Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS

Proteomics - Clinical Applications

Volumn 4, Issue 3, 2010, Pages 352-357

  Albertini, Valentina ^a   Bruno, Anna ^a   Paterlini, Anna ^a   Lista, Simone ^b   Benussi, Luisa ^a   Cereda, Cristina ^b   Binetti, Giuliano ^a   Ghidoni, Roberta ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

6E10 and 4G8; Alzheimer's disease; Cerebrospinal fluid; N and C terminally truncated amyloid peptides; PS20 ProteinChip array

Indexed keywords

AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY; REAGENT;

AGED; CLINICAL PROTOCOL; COGNITIVE DEFECT; CONTROLLED STUDY; ECONOMIC ASPECT; HUMAN; HUMAN TISSUE; NOTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOASSAY; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77951718059     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900166     Document Type: Note

References (22)

1. Hardy, J.A., Higgins, G.A., Alzheimer's disease: The amyloid cascade hypothesis. Science 1992, 256, 184-185.
2. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
3. Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C. et al., Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359, 322-325.
4. Sisodia, S.S., Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. USA 1992, 89, 6075-6079.
5. Jarrett, J.T., Berger, E.P., Lansbury, P.T., The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32, 4693-4697.
6. Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H. et al., Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13, 45-53.
7. Iwatsubo, T., Saido, T.C., Mann, D.M., Lee, V.M., Trojanowski, J.Q., Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am. J. Pathol. 1996, 149, 1823-1830.
8. Russo, C., Saido, T.C., DeBusk, L.M., Tabaton, M. et al., Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett. 1997, 409, 411-416.
9. Vanderstichele, H., De Meyer, G., Andreasen, N., Kostanjevecki, V. et al., Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin. Chem. 2005, 51, 1650-1660.
10. Simonsen, A.H., Hansson, S.F., Ruetschi, U., McGuire, J. et al., Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dement. Geriatr. Cogn. Disord. 2007, 23, 246-250.
11. Maddalena, A.S., Papassotiropoulos, A., Gonzalez-Agosti, C., Signorell, A. et al., Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener. Dis. 2004, 1, 231-235.
12. Lewczuk, P., Esselmann, H., Meyer, M., Wollscheid, V. et al., The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun. Mass Spectrom. 2003, 17, 1291-1296.
13. Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., Blennow, K., Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 2006, 5, 1010-1016.
14. Portelius, E., Zetterberg, H., Andreasson, U., Brinkmalm, G. et al., An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci. Lett. 2006, 409, 215-219.
15. Portelius, E., Tran, A.J., Andreasson, U., Persson, R. et al., Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 2007, 6, 4433-4439.
16. Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A. et al., Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 2002, 81, 481-496.
17. Ghidoni, R., Albertini, V., Squitti, R., Paterlini, A. et al., Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. J. Alzheimers Dis. 2009, 18, 295-303.
18. Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T. et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6, 734-746.
19. Sergeant, N., Bombois, S., Ghestem, A., Drobecq, H. et al., Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 2003, 85, 1581-1591.
20. Liu, K., Solano, I., Mann, D., Lemere, C. et al., Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol. 2006, 112, 163-174.
21. Piccini, A., Zanusso, G., Borghi, R., Noviello, C. et al., Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch. Neurol. 2007, 64, 738-745.
22. Hecimovic, S., Wang, J., Dolios, G., Martinez, M. et al., Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol. Dis. 2004, 17, 205-218.